JP2020529457A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529457A5
JP2020529457A5 JP2020506940A JP2020506940A JP2020529457A5 JP 2020529457 A5 JP2020529457 A5 JP 2020529457A5 JP 2020506940 A JP2020506940 A JP 2020506940A JP 2020506940 A JP2020506940 A JP 2020506940A JP 2020529457 A5 JP2020529457 A5 JP 2020529457A5
Authority
JP
Japan
Prior art keywords
compound according
compound
nhr
linker
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020506940A
Other languages
English (en)
Japanese (ja)
Other versions
JP7218351B2 (ja
JP2020529457A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/071507 external-priority patent/WO2019030284A1/en
Publication of JP2020529457A publication Critical patent/JP2020529457A/ja
Publication of JP2020529457A5 publication Critical patent/JP2020529457A5/ja
Application granted granted Critical
Publication of JP7218351B2 publication Critical patent/JP7218351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020506940A 2017-08-09 2018-08-08 新たな標的化された細胞傷害性ラトジャドン誘導体及びそのコンジュゲート Active JP7218351B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17185598.4 2017-08-09
EP17185598 2017-08-09
PCT/EP2018/071507 WO2019030284A1 (en) 2017-08-09 2018-08-08 NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF

Publications (3)

Publication Number Publication Date
JP2020529457A JP2020529457A (ja) 2020-10-08
JP2020529457A5 true JP2020529457A5 (https=) 2021-09-24
JP7218351B2 JP7218351B2 (ja) 2023-02-06

Family

ID=59579518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020506940A Active JP7218351B2 (ja) 2017-08-09 2018-08-08 新たな標的化された細胞傷害性ラトジャドン誘導体及びそのコンジュゲート

Country Status (6)

Country Link
US (1) US11236059B2 (https=)
EP (1) EP3665161B1 (https=)
JP (1) JP7218351B2 (https=)
AU (1) AU2018315154B2 (https=)
CA (1) CA3072399A1 (https=)
WO (1) WO2019030284A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020220085A1 (en) * 2019-05-02 2020-11-05 The University Of Sydney Peptide derivatives and conjugates thereof for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
DE19636721A1 (de) 1996-09-10 1998-03-12 Biotechnolog Forschung Gmbh Antibiotische und antitumorale Verbindung, Herstellungsverfahren, Mittel und DSM 11 071
DE10106647A1 (de) 2001-02-12 2002-08-22 Univ Hannover Ratjadon-Derivate zum Hemmen des Zellwachstums
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AU2007254821B2 (en) * 2006-06-01 2013-11-14 Bayer Consumer Care Ag Sustained release pharmaceutical formulation comprising phenylephrine
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
FI2911699T4 (fi) 2012-10-23 2025-12-09 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN105592861A (zh) * 2013-08-02 2016-05-18 赛诺菲 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途

Similar Documents

Publication Publication Date Title
JP2020536091A5 (https=)
TWI455946B (zh) 抗磷脂醯肌醇蛋白聚糖3抗體
JP2019512478A5 (https=)
JP2020525426A5 (https=)
JP2016153410A5 (https=)
JP2017536344A5 (https=)
JP2005532287A5 (https=)
JP2019514426A5 (https=)
JP2018510864A5 (https=)
JP2016525466A5 (https=)
JP2011500725A5 (https=)
JP2018504379A5 (https=)
JP2010503698A5 (https=)
JP2015051994A5 (https=)
JP2021121590A5 (https=)
JP2010529986A5 (https=)
JP2011506274A5 (https=)
JP2009541288A5 (https=)
JP2014504599A5 (https=)
JP2008520662A5 (https=)
JP2020529457A5 (https=)
JP2008540414A5 (https=)
JP2011527678A5 (https=)
JP2024501120A (ja) 化学合成のための組成物及び方法
JP2021503522A5 (https=)